Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease

By C. Korth, B. C. May, Fred E. Cohen, S. Prusiner. Proceedings of the National Academy of Sciences of the United States of America, 2001

620 citations recorded by the source corpus.

Subfields: Molecular Biology, Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/694ffc3af496def6c2bb3ffe272b2285d7786ce4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Fred E. Cohen
2. J. Kelly

In Neurology

1. Fred E. Cohen

In Physiology

1. J. Kelly

Citations in the corpus

• Therapeutic approaches to protein-misfolding diseases (2003, background): “A variety of compounds including anthracyclines, porphyrins and diazo dyes block prion replication when administered with PrP Sc , the aggregated infectious form of the prion protein, into animal model”
• Protein aggregation diseases: pathogenicity and therapeutic perspectives (2010, background): “Another class of drugs that may prevent the aggregation of PrP Sc are the antimalarial compounds quinacrine and chloroquin”